Preferential production of IgM-secreting hybridomas by immunization with DNA vaccines coding for Ebola virus glycoprotein: use of protein boosting for IgG-secreting hybridoma production.
10.7774/cevr.2017.6.2.135
- Author:
Si Hyeong LEE
1
;
Baek Sang HAN
;
Jongseon CHOE
;
Jeong Im SIN
Author Information
1. BK21 Plus Graduate Program and Department of Microbiology, School of Medicine, Kangwon National University, Chuncheon, Korea. jsin1964@hanmail.net
- Publication Type:Original Article
- Keywords:
Ebola virus;
Hybridoma;
DNA vaccines;
Glycoprotein;
Antibody production
- MeSH:
Animals;
Antibodies;
Antibodies, Monoclonal;
Antibody Formation;
Blotting, Western;
Clinical Coding*;
DNA*;
Ebolavirus*;
Enzyme-Linked Immunosorbent Assay;
Glycoproteins*;
Hemorrhagic Fever, Ebola;
Hybridomas*;
Immunization*;
Immunoglobulin G;
Immunoglobulin M;
Mice;
Vaccination;
Vaccines, DNA*
- From:Clinical and Experimental Vaccine Research
2017;6(2):135-145
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: The goal of this study was to investigate the utility of DNA vaccines encoding Ebola virus glycoprotein (GP) as a vaccine type for the production of GP-specific hybridomas and antibodies. MATERIALS AND METHODS: DNA vaccines were constructed to express Ebola virus GP. Mice were injected with GP DNA vaccines and their splenocytes were used for hybridoma production. Enzyme-linked immunosorbent assays (ELISAs), limiting dilution subcloning, antibody purification methods, and Western blot assays were used to select GP-specific hybridomas and purify monoclonal antibodies (MAbs) from the hybridoma cells. RESULTS: Twelve hybridomas, the cell supernatants of which displayed GP-binding activity, were selected by ELISA. When purified MAbs from 12 hybridomas were tested for their reactivity to GP, 11 MAbs, except for 1 MAb (from the A6-9 hybridoma) displaying an IgG2a type, were identified as IgM isotypes. Those 11 MAbs failed to recognize GP. However, the MAb from A6-9 recognized the mucin-like region of GP and remained reactive to the antigen at the lowest tested concentration (1.95 ng/mL). This result suggests that IgM-secreting hybridomas are predominantly generated by DNA vaccination. However, boosting with GP resulted in greater production of IgG-secreting hybridomas than GP DNA vaccination alone. CONCLUSION: DNA vaccination may preferentially generate IgM-secreting hybridomas, but boosting with the protein antigen can reverse this propensity. Thus, this protein boosting approach may have implications for the production of IgG-specific hybridomas in the context of the DNA vaccination platform. In addition, the purified monoclonal IgG antibodies may be useful as therapeutic antibodies for controlling Ebola virus infection.
